Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar. Closed at $2.60, 62% below $6.76, its close on the day of its Oct 9 registered direct offering. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$20.6MCash, Pro Forma
53.7mo Cash Runway
Follow SBFM by emailGet an email when SBFM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SBFM, unsubscribe in one click. Privacy
📣 What SBFM Says Is Next
in 2026 · “Based on current plans, these initiatives are expected to reduce expenses by approximately $2 million to $3 million in 2026, although there can be no assurance that these reductions will be fully realized. 1 About Sunshine Biopharma Sunshine Biopharma currently markets 71 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026.”
Company press release, Apr 9, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Shareholder vote Sunshine Biopharma will hold its 2026 annual shareholder meeting online on December 29, 2026, with a record date of November 4, 2026. Shareholders will vote on electing five directors, ratifying M&K CPAS, PLLC as auditor, and raising the 2023 Equity Incentive Plan share cap to 7,000,000. Form DEF 14A · SEC filing
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 2, 2026 ·
Financing Sunshine Biopharma proposes a best-efforts offering of up to 10,180,337 common units, each with one share and two Series D Warrants, plus pre-funded units, with the public offering price assumed at $0.6876 per unit. Aegis Capital Corp. is sole placement agent, and the offering is expected to close by November 30, 2026. Form S-1 · SEC filing
Sep 16, 2026 ·
Shareholder vote Majority holder Dr. Steve N. Slilaty, who holds about 97% of voting power, approved by written consent a reverse split of up to 1-for-20, at the board's discretion. The consent takes effect 20 days after the information statement is mailed. Form 8-K · SEC filing
Sep 11, 2026 ·
Financing Due to recent sales of common stock under its at-the-market offering, the exercise price of the Series B Warrants has been reduced to $1.2046, subject to further adjustment under the warrant terms. Form 8-K · SEC filing
Sep 8, 2026 ·
Financing Sunshine Biopharma is registering 25,477,133 shares of common stock issuable on exercise of outstanding Series B Warrants at a current exercise price of $1.2202, which would bring about $31 million if all are exercised for cash. The stock is at risk of Nasdaq delisting for failing the $1.00 minimum bid price rule. Form 424B3 · SEC filing
Aug 28, 2026 ·
Leadership Director Dr. Andrew Keller notified the company on August 25, 2026 that he will not seek or accept reelection to the Board when his current term expires at the next annual shareholder meeting. Form 8-K · SEC filing
Aug 28, 2026 ·
Financing Sunshine Biopharma filed a registration statement to register 25,477,133 shares issuable on exercise of outstanding Series B Warrants at a current exercise price of $1.2202, which would bring about $31 million if all are exercised for cash. The company also disclosed Nasdaq bid price and market value listing risks. Form S-1 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 2 · Recruiting · A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients Registry primary completion date, not a results date
Dec 2026 · Phase 1 · Recruiting · A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors Registry primary completion date, not a results date
Dec 2026 · Phase 1 · Recruiting · A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects Registry primary completion date, not a results date
Dec 2026 · Phase 1 · Recruiting · Single-ascending Dose Study of HEC-151 Injection Registry primary completion date, not a results date
Dec 2026 · Phase 1 · Recruiting · A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects Registry primary completion date, not a results date
Jan 2027 · Phase 3 · Recruiting · A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not SBFM's own candidates): Insulin Degludec, Cytarabine, Decitabine, Pirfenidone, Azacitidine, Colchicine, Gefitinib, Bevacizumab, Capecitabine, Oxaliplatin, Nintedanib, Efavirenz.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
SBFM had $14.6M in cash and short-term investments on its Sep 30, 2026 balance sheet.
Including the cash events since then, it holds about $20.6M pro forma, before operating spending after that date:
Closed public offering, announced Oct 9, 2026 (gross proceeds): $6M · 8-K
It burns about $1.2M/quarter from operations, an estimated runway of 53.7 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).
Dilution pressure:25 · Moderate
Cash runway 54 months (pro forma for cash events since the balance sheet)
ATM program on file since Jul 2026 +15
Shelf registration (S-3, Jan 2025) +10
Recent financing filings on SEC EDGAR:
Oct 9, 2026 · Registered direct / best-efforts offering · 424B4
Oct 2, 2026 · Registered direct / best-efforts offering · S-1
Share count 823,772 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SBFM picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SBFM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.